The NIH-funded Northeastern University Center for Translational Cancer Nanomedicine (CTCN) was established in September 2010 as part of Phase 2 of the National Cancer Institute's Alliance for Nanotechnology in Cancer program with collaborators at Beth Israel Deaconess Hospital; Harvard Medical School; Tufts University, Auburn University and Nemucore Medical Innovations, Inc. The CTCN will utilize the support and facilities of the NU-based Center for High-rate Nanomanufacturing.
Northeastern University CTCN is one of only nine Centers of Cancer Nanotechnology Excellence (CCNE) across the country that has been awarded a five-year $13.5 million grant from the NCI Alliance in an open nationwide competition.
Building upon Northeastern’s strong base of interdisciplinary nanotechnology research, the center will create new drugs that target cancer cells, advance technology on how nanocarriers deliver these drugs, and utilize imaging tools that track how they travel through the body. To enable the translation of these nanomedicines from bench to bedside, test batches of the nanopreparations will be developed for preclinical use to meet FDA standards for further clinical testing. The team will also develop semi-industrial and industrial processes to scale up their production.
Cross-disciplinary collaboration will enable integration of the fundamental biological knowledge base with physical science and engineering approaches for intimate involvement in scale-up and manufacture to rapidly translate bench research into animal testing and GMP production and to narrow the gap between discovery and development of anticancer therapeutics. The CTCN will concentrate on multifunctional, targeted devices that will bypass current biological barriers to delivery of multiple therapeutic agents at high local concentrations, with appropriate timing, directly to cancer cells.